Ultragenyx Pharmaceutical
RARE
151 hedge funds and large institutions have $3.33B invested in Ultragenyx Pharmaceutical in 2015 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 40 reducing their positions, and 13 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
192% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 13
70% more capital invested
Capital invested by funds: $1.96B → $3.33B (+$1.36B)
43% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 40
20% more funds holding
Funds holding: 126 → 151 (+25)
45% less call options, than puts
Call options by funds: $6.53M | Put options by funds: $11.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$63.5M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$52.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$24.6M |
| 4 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
+$20.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$77.6M |
| 2 |
Millennium Management
New York
|
-$38.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$34.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$25.2M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$23.3M |
RARE Hedge Fund Activity: Q2 2015 in Review
151 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2015, worth a combined $3.33B — up 70% from $1.96B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new RARE positions and 13 closed out — a net gain of 25 holders — while 57 added to existing stakes and 40 trimmed.
The largest buyer was Wells Fargo, adding an estimated $63.5M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $77.6M.
- 151 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2015, up from 126 in Q1 2015.
- Funds reported $3.33B of Ultragenyx Pharmaceutical stock for Q2 2015, up 70% quarter-over-quarter.
- 38 funds opened new Ultragenyx Pharmaceutical positions in Q2 2015 and 13 closed out, a net change of +25 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2015 was Wells Fargo, an estimated $63.5M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2015 was TPG Group Holdings (SBS) Advisors, an estimated $77.6M sold.
Based on aggregated 13F filings for Q2 2015.